Broadcom named strategic vendor for Walmart virtualization solutions
Derek Maetzold, President and CEO of Castle Biosciences Inc . (NASDAQ:CSTL), recently executed a series of stock sales totaling $114,573. Castle Biosciences, with a market capitalization of $567 million, maintains a strong financial position according to InvestingPro analysis, which rates the company’s overall financial health as "GREAT" with a score of 3.42 out of 5. The transactions were carried out on March 26, 2025, under a pre-arranged trading plan. The sales involved multiple trades of common stock at an average price of $20.30 per share, with prices ranging from $20.01 to $20.72. The stock currently trades at $19.91, with analysts setting price targets between $36 and $44. According to InvestingPro data, the company holds more cash than debt on its balance sheet, indicating strong liquidity. Following these sales, Maetzold holds various quantities of shares through different trusts, including the Maetzold Descendants 2020 Trust and others designated for family members. For deeper insights into insider trading patterns and comprehensive financial analysis, including 10+ additional ProTips, explore the full Castle Biosciences research report on InvestingPro.
In other recent news, Castle Biosciences Inc. reported a notable earnings performance for the fourth quarter of 2024, significantly surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.32, far exceeding the forecasted $0.01. Additionally, Castle Biosciences’ revenue for the quarter reached $86.3 million, surpassing the anticipated $80.54 million. For the full year 2024, the company reported a 51% increase in revenue to $332.1 million and a net income of $18.2 million, a reversal from a net loss of $57.5 million in 2023.
Despite the strong financial results, Castle Biosciences faces challenges, including potential Medicare reimbursement issues for its SCC test, which could impact future revenue. The company has projected 2025 revenue between $280 million and $295 million, with gross margins expected in the low-to-mid 70% range. Looking ahead, Castle Biosciences plans to continue investing in its current product lines and explore potential strategic mergers and acquisitions to drive growth. Analyst firms have not issued recent upgrades or downgrades, but the company’s financial outlook remains under scrutiny due to reimbursement uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.